BMA BIOMEDICALS

Peninsula Laboratories

T-4871
Rabbit anti-Activity-Dependent Neuroprotective Protein (ADNP) (74-81) (mouse, rat), NAP, Davunetide

Davunetide is an intranasal neuropeptide therapy derived from a growth factor called activity-dependent neurotrophic protein (ANAP). It is released by glial cells. This peptide has highly potent neuroprotective activity.

This antibody was generated by immunization of rabbits with Davunetide coupled to a carrier protein.

TECHNICAL AND ANALYTICAL CHARACTERISTICS

Lot number:	A13766
Host species:	Rabbit IgG
Quantity:	5ml
Format:	This polyclonal antibody is supplied as a lyophilized powder. The powder should be rehydrated with 5ml of ELISA buffer. Upon reconstitution to 50ml total volume, the solution contains 0.1M sodium phosphate buffer (pH 7.4), 0.05M NaCl, 0.1% BSA, 0.01% NaN_3, and 0.1% Triton X-100. Store at 4° - 8°C. This should ensure antibody stability for approximately one month.
Stability:	Original vial: at least one year at 4° - 8°C from date of delivery. Minimize repeated thawing and freezing of the antiserum by freezing aliquots at -20°C or below.
Applications:	This antibody has been tested and validated in ELISA against Davunetide. Other applications like immunohistochemistry (IHC), FACS or Western Blot may work as well. Optimal dilutions should be determined by the end user. Please see **www.bma.ch** for protocols and general information.
Immunogen:	Synthetic peptide H-Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln-OH coupled to carrier protein.

Cross-Reactivity:

PEPTIDE	**%**
Activity-Dependent Neuroprotective Protein (74-81), Davunetide	100

This product contains Thimerosal as a preservative and is intended for laboratory use and research purposes only. Purchase of this product does not include authorization to use it in diagnostic or therapeutic applications.

BMA BIOMEDICALS, Rheinstrasse 28-32, CH-4302 Augst (Switzerland)
Phone: +41 61 811 6222, Fax: +41 61 811 6006, info@bma.ch, www.bma.ch